Introducing new medicine at the intercept of microbiology and immunology

UNION is a privately held, clinical stage, pharmaceutical company dedicated to the discovery and development of novel medicine for patients with an unmet need. UNION’s chemistry platform utilizes direct microbiological and immunomodulatory effects, enabling treatments across a versatile range of indications.

About

UNION comprises a global team with drug development experience from more than 10 successfully marketed medicines. These medicines have saved thousands of lives and improved life quality in patients and their relatives.

News & Events

Read about our latest news and find out which upcoming events UNION will participate in. For news or event overview, click below.

Pipeline

Learn about UNION’s pipeline. In particular, ATx201 which is our lead candidate and is being developed for topical treatment of the inflammatory diseases: atopic dermatitis and rosacea.

Artikel

Indhold her.

Join our team

UNION constantly seeks like-minded and talented drug developers, scientists, and business developers at any
level who share our passion for improving the health of humans suffering from infectious and inflammatory disorders.

UNION therapeutics A/S
Tuborg Havnevej 18
DK-2900 Hellerup
Denmark
info@uniontherapeutics.com
+45 6177 7435
CVR: 33963750

Quick links

Investor and Media Relations

UNION therapeutics Investor Relations
Tuborg Havnevej 18
DK-2900 Hellerup
Denmark
investor@uniontherapeutics.com
+45 2381 5487
CVR: 33963750

UNION Therapeutics